ABSTRACT. The response of hematopoietic progenitors hGH and IGF-I are polypeptides that regulate proliferation to the growth promoting effects of hGH and IGF-I has and metabolic processes in a variety of mammalian cell types been documented. In this study, the effects of recombinant (1). Considerable evidence exists indicating an effect of these hGH and IGF-I on the growth of circulating erythroid peptides in normal human erythropoiesis. Both hGH and IGF-I burst forming cells (BFU-E) from growth-IGF-I retarded induce potentiation of colony formation by erythroid (BFU-E) children with insufficient growth hormone secretion as well as myeloid progenitor cells from normal human donors (IGHS) were evaluated and compared with values obtained (2-5). IGF-I, which is presumed to mediate the effect of GH in from either children with short stature and normal growth various tissues, probably is the mediator of GH in erythropoiesis hormone levels (SNGH) or normal donors. Both recombi-(4), although some reports suggest a direct effect of hGH on nant hGH and IGF-I had significantly greater stimulatory BFU-E (1, 2, 6). Studies on leukemic cell lines as well as on effects on the growth of BFU-E from the IGHS compared freshly obtained marrow cells from children with acute leukemia with the SNGH and with the normally growing children. also indicate that hGH and IGF-I may enhance in vitro human At its optimal concentration of 200 pg/L, recombinant hGH leukemic cell proliferation (7). had a stimulatory effect on the growth of BFU-E from 11
effects of hGH and IGF-I may be the result of increased availability of cell surface receptors to these hematopoietic
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modification of the assay of Dukes et al. (1 1 IGF-I-induced enhancement of BFU-E was detected at a concentration of 0.032 nmol/L (0.25 ng/mL) and was maximal at 0.065 nmol/L (0.5 ng/mL) (Fig. 2) . Potentiation of BFU-E colony formation in cell cultures from the IGHS children, using 0.5 ng/mL recombinant IGF-I (1.67 + 0.25-fold of control BFU-E; p < 0.007), was significantly greater ( p < 0.006) than the (Fig. 3) . The frequency of the observed IGF-I-induced increase in BFU-E growth of >1.5-fold was 67% (six of nine) of the IGHS children, 17% (one of six) of the SNGH children, and none (zero of five) of the normal control group. The specificity of the described hormone-induced growthpotentiating effects was studied in the PB cultures of three IGHS patients and was demonstrated by the complete neutralization of the hGH-induced effect using. an anti-hGH antibody (at a dilution of 1 :200) and of the IGF-I-induced effect using an anti-IGF-I antibody (at a dilution of 1:1000) (Fig. 4) .
DISCUSSION
Previous studies have demonstrated that hGH and IGF-I enhance in vitro proliferation of erythroid precursors (2, 4-6), and recent reports also have shown that both hGH and IGF-I enhance the in vitro growth of human bone marrow derived granulomonocytic colonies (3) and of leukemic blast colonies (7) . Growth-retarded children with isolated GH deficiency are not regularly presented with significant anemia, although this finding has been postulated by at least one report (5) . It has been long established, however, that hypophysectomized animals are anemic and that patients with pituitary malfunction suffer from a similar condition (12, 13) . The anemia and the impaired DNA 284 BARAK ET AL. Fig. 4 . Neutralization of h G H a n d IGF-I-induced enhancement of P B BFU-E growth by anti-hGH a n d IGF-I antibodies (AB). Each bar represents the mean * SD of BFU-E from the peripheral blood of three lGHS patients expressed as % of control. AntihGH a n d IGF-I AB were added at 1 :200 and 1: 1000 dilutions, respectively. and RNA synthesis in the bone marrow of hypophysectomized rats could be restored by GH (14) , whereas treatment of prepubertal hypopituitary dwarfs with hGH in doses sufficient to induce linear growth induced increased hematopoiesis (13) . In contrast, hGH failed to enhance erythropoiesis in acromegalic patients (1 5) .
This study compares the response to hGH and to IGF-I of erythropoietic progenitor cells from 1 1 patients with insufficient G H secretion [a short-stature disorder characterized by a subnormal spontaneous GH secretion but a normal response to provocative tests, previously termed "neurosecretory dysfunction" (16) ] with the response of cells from six growth-retarded patients with normal GH levels and five normally growing children. Focusing on growth-retarded children with IGHS as the study group seems to be appropriate because several reports have claimed that children with IGHS may represent a subset of growth-retarded patients with subnormal GH levels who could benefit from hGH therapy (8, 16, 17) . Indeed, treatment of IGHS children for 2 y with hGH elicits a marked growth response similar to that noted in patients with a subnormal GH response to provocative tests (18) . BFU-E from the IGHS children were significantly more responsive to the erythropoietic potentiating effects of both hGH and IGF-I than to BFU-E from the growthretarded patients with normal GH levels or from normal donors.
The mechanism whereby hGH, alone or mediated by IGF-I, enhances the in vitro growth of human erythroid progenitors is not clear. Recent studies have shown that murine Friend erythroleukemia cells were specifically stimulated by GH (19) and, furthermore, that hGH acted as a potent direct stimulator of the human erythroleukemia cell line K562 (20) . Indeed, membrane receptors for IGF-I have been detected in human erythrocytes (21) .
Recently, attention has been directed toward several growth factors that do not stimulate hematopoietic colony formation directly but enhance the response of hematopoietic stem cells to specific proliferative and differentiative signals of terminal growth factors. GH and IGF-I may be classified as an example of those "synergistic hematopoietic growth factors" (22) . It has been suggested that exposure to these synergistic hormones may be required for the initiation of DNA synthesis and hematopoietic cell division. Although the mechanism of this synergism is not clear, an attractive hypothesis, supported by some experimental evidence (23), suggests the induction of enhanced receptor expression in primitive stem cells, more ofwhich then become responsive to specific inducers of terminal differentiation. The cause for the significantly greater response of erythroid progenitors from patients with insufficient GH secretion to the synergistic hematopoietic effect of both GH and IGF-I remains unresolved. Because clinically a correlation exists between the initial GH levels and the achieved linear growth in growth-retarded patients under hGH therapy (18) , by analogy the increase in responsiveness of their hematopoietic cells to GH and to IGF-I may be the result of an increased availability of cell surface receptors to these peptides, secondary to their decreased circulating concentrations in vivo. In disorders associated with increased circulating GH levels such as acromegaly, no erythropoietic effect of GH could be detected (15) . The performance of receptorbinding studies would have undoubtedly elucidated the mechanisms involved in the effects of "synergistic" factors in the enhancement of in vitro erythropoiesis in IGHS patients. Unfortunately, these were not performed in the present study because it is extremely difficult to isolate human PB hematopoietic progenitors in sufficient quantity for such studies. Changes in the BFU-E response to hGH and IGF-I in these patients, after hGH therapy, is under investigation.
These findings indicate that in vitro studies of erythroid progenitor responsiveness to GH and to IGF-I may be useful in implicating those peptides in growth retardation, as well as in predicting in vivo responses to them. In addition, the findings suggest a possible hematopoietic synergistic effect of GH or IGF-I in children with other disorders such as end-stage renal disease, a condition characterized by erythropoietin responsive anemia (24) , in which growth retardation currently is being treated by hGH (25) . The potential synergism between the hormones hGH and IGF-I and the hematopoietic growth factor rEpo on erythropoietic cell growth in these children is under investigation.
